These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

126 related articles for article (PubMed ID: 1743631)

  • 21. Treatment of children and young adults with early-stage non-Hodgkin's lymphoma.
    Link MP; Shuster JJ; Donaldson SS; Berard CW; Murphy SB
    N Engl J Med; 1997 Oct; 337(18):1259-66. PubMed ID: 9345074
    [TBL] [Abstract][Full Text] [Related]  

  • 22. High-dose cyclophosphamide-high-dose methotrexate with coordinated intrathecal therapy for advanced nonlymphoblastic lymphoma of childhood: results of a Pediatric Oncology Group study.
    Sullivan MP; Brecher M; Ramirez I; Ragab A; Hvizdala E; Pullen J; Shuster J; Berard C; Crist W; Vietti T
    Am J Pediatr Hematol Oncol; 1991; 13(3):288-95. PubMed ID: 1793154
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Brief-duration high-intensity chemotherapy for patients with small noncleaved-cell lymphoma or FAB L3 acute lymphocytic leukemia: results of cancer and leukemia group B study 9251.
    Lee EJ; Petroni GR; Schiffer CA; Freter CE; Johnson JL; Barcos M; Frizzera G; Bloomfield CD; Peterson BA
    J Clin Oncol; 2001 Oct; 19(20):4014-22. PubMed ID: 11600602
    [TBL] [Abstract][Full Text] [Related]  

  • 24. High rate and prolonged duration of complete remissions induced by rituximab, methotrexate, doxorubicin, cyclophosphamide, vincristine, ifosfamide, etoposide, cytarabine, and thalidomide (R-MACLO-IVAM-T), a modification of the National Cancer Institute 89-C-41 regimen, in patients with newly diagnosed mantle cell lymphoma.
    Lossos IS; Hosein PJ; Morgensztern D; Coleman F; Escalón MP; Byrne GE; Rosenblatt JD; Walker GR
    Leuk Lymphoma; 2010 Mar; 51(3):406-14. PubMed ID: 20038221
    [TBL] [Abstract][Full Text] [Related]  

  • 25. A phase II trial of ProMACE-CytaBOM in previously untreated non-Hodgkin's lymphoma of intermediate- or high-grade histology.
    Rossi G; Mariano MR; Arcangeli G; Bonfanti V; Capucci MA; Ferremi P; Marpicati P; Meriggi F; Zaniboni A; Izzi T
    Hematol Oncol; 1991; 9(3):147-55. PubMed ID: 1718837
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Treatment of diffuse non-Hodgkin's lymphoma with combined chemotherapy using methotrexate, adriamycin, cyclophosphamide, vincristine, prednisolone and bleomycin (MACOP-B).
    Sawada U; Yamazaki T; Suzuki K; Ashiya M; Satou Y; Hirano H; Tsuboi I; Sakuma A; Kura Y; Kouda K
    Int J Hematol; 1992 Aug; 56(1):59-66. PubMed ID: 1382663
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Poor-risk non-lymphoblastic lymphoma of childhood: results of an intensive pilot study.
    Finlay JL; Trigg ME; Link MP; Frierdich S
    Med Pediatr Oncol; 1989; 17(1):29-38. PubMed ID: 2913472
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Etoposide, ifosfamide, and methotrexate combination chemotherapy for aggressive non-Hodgkin's lymphomas after failure of the LNH 84 regimen.
    Herbrecht R; Damonte JC; Dufour P; Maloisel F; Liu KL; Ortiz S; Bergerat JP; Oberling F
    Semin Oncol; 1992 Feb; 19(1 Suppl 1):7-10. PubMed ID: 1384135
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Adults and children with small non-cleaved-cell lymphoma have a similar excellent outcome when treated with the same chemotherapy regimen.
    Magrath I; Adde M; Shad A; Venzon D; Seibel N; Gootenberg J; Neely J; Arndt C; Nieder M; Jaffe E; Wittes RA; Horak ID
    J Clin Oncol; 1996 Mar; 14(3):925-34. PubMed ID: 8622041
    [TBL] [Abstract][Full Text] [Related]  

  • 30. [Treatment of aggressive non-Hodgkin's lymphoma with the ProMACE- CytaBOM protocol].
    Mihaljević B; Jancić-Nedeljkov R; Sretenović M; Milivojević G; Janković S; Petrović M
    Srp Arh Celok Lek; 1998; 126(9-10):345-8. PubMed ID: 9863405
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Ifosfamide, epirubicin and etoposide (IEV) therapy in relapsed and refractory high-grade non-Hodgkin's lymphoma and Hodgkin's disease.
    Zinzani PL; Barbieri E; Visani G; Gherlinzoni F; Perini F; Neri S; Bendandi M; Ammendolia I; Salvucci M; Babini L
    Haematologica; 1994; 79(6):508-12. PubMed ID: 7534744
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Sequential versus alternating chemotherapy for high-grade non-Hodgkin's lymphomas: preliminary results of a phase III multicentre trial.
    Köppler H; Pflüger KH; Eschenbach I; Pfab R; Bruntsch U; Zeller W; Steinhauer EU; Gropp C; Oehl S; Lötzke E
    Onkologie; 1990 Feb; 13(1):28-32. PubMed ID: 2186321
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Advances in chemotherapy for large cell lymphoma.
    Coleman M; Gerstein G; Topilow A; Lebowicz J; Berhardt B; Chiarieri D; Silver RT; Pasmantier MW
    Semin Hematol; 1987 Apr; 24(2 Suppl 1):8-20. PubMed ID: 2438781
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Twin-track studies of ifosfamide and mitoxantrone (I-M) in recurrent high grade non-Hodgkin's lymphoma and Hodgkin's disease. Yorkshire Regional Lymphoma and Central Lymphoma Groups.
    Child JA; Simmons AV; Barnard DL; Parapia L; Morgan M; Grace RJ; Fletcher J; Parker D; Norfolk DR; Stone J
    Hematol Oncol; 1991; 9(4-5):235-44. PubMed ID: 1743626
    [TBL] [Abstract][Full Text] [Related]  

  • 35. VP-16, ifosfamide, and methotrexate combination chemotherapy for aggressive non-Hodgkin's lymphomas after failure of the LNH 84 regimen.
    Herbrecht R; Garcia JJ; Bergerat JP; Dufour P; Duclos B; Oberling F
    Cancer Chemother Pharmacol; 1989; 24(5):338-9. PubMed ID: 2474382
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Improved treatment results of non-Hodgkin's lymphoma in children: a report from the Children's Cancer and Leukemia Study Group of Japan.
    Shimizu H; Kikuchi M; Takaue Y; Utsumi J; Takeda T; Fujimoto T
    Int J Hematol; 1995 Feb; 61(2):85-96. PubMed ID: 7734716
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Combination chemotherapy for intermediate and high grade non-Hodgkin's lymphoma.
    Dhaliwal HS; Rohatiner AZ; Gregory W; Richards MA; Johnson PW; Whelan JS; Gallagher CJ; Matthews J; Ganesan TS; Barnett MJ
    Br J Cancer; 1993 Oct; 68(4):767-74. PubMed ID: 8398705
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Comparison of a standard regimen (CHOP) with three intensive chemotherapy regimens for advanced non-Hodgkin's lymphoma.
    Fisher RI; Gaynor ER; Dahlberg S; Oken MM; Grogan TM; Mize EM; Glick JH; Coltman CA; Miller TP
    N Engl J Med; 1993 Apr; 328(14):1002-6. PubMed ID: 7680764
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Treatment outcome and prognostic factors for relapse after high-dose chemotherapy and peripheral blood stem cell rescue for patients with poor risk high grade non-Hodgkin's lymphoma.
    Lee SM; Ryder WD; Clemons MJ; Morgenstern GR; Chang J; Scarffe JH; Radford JA
    Bone Marrow Transplant; 1999 Aug; 24(3):271-7. PubMed ID: 10455365
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Effects of Mega-COMLA (cyclophosphamide, cytarabine, vincristine, and methotrexate followed by leucovorin and prednisone) plus CHOP (cyclophosphamide, doxorubicin, vincristine, and prednisone) in the treatment of lymphoid neoplasms with very poor prognosis.
    Hainsworth JD; Wolff SN; Stein RS; Greer JP; Cousar JB; Greco FA
    Cancer Treat Rep; 1986 Aug; 70(8):953-8. PubMed ID: 3015406
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.